Protagonist Therapeutics
Discovers peptide drugs and partnered icotrokinra with Johnson & Johnson and rusfertide with Takeda.
Share price
$144
Up 111% over 12 monthsWhat analysts expect
Buy
Buy100%
Hold0%
Sell0%
Price target for the next 12 months
$154Up 15% compared with the current price
Price now $134Average targetLowest $82.00 to highest $190
18 analysts. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- $282M
- Yearly profit
- $83M
- Company value
- $9.3B
- Forward P/E
- 64.7×As of 2026-10-21
- Forward P/S
- 23.0×As of 2026-10-21
Revenue and profit for the last twelve months reported.
Forward P/E compares the share price with forecast earnings per share. Forward P/S compares company value with forecast revenue. Both are dated estimates, separate from the live price. Missing or non-positive estimates are shown as unavailable.
Peptides in this book
- IcotrokinraPrescription
- RusfertidePrescription
Recent news
- 2026-08-31 FDA approves rusfertide (Mimrylo) for polycythemia vera Accesswire
- 2026-09-08 Protagonist announces 300 million USD share repurchase program Accesswire
Logo source: Protagonist Therapeutics
Prices are delayed and figures rounded. Not investment advice.